Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs BG 00011 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms SPIRIT
- Sponsors Biogen
- 30 Jun 2022 Results reporting endpoints evaluated at week 26 as an exploratory analysis published in the American Journal of Respiratory and Critical Care Medicine
- 24 Dec 2021 This trial is completed in Belgium (End date - 2019-11-14) , as per European Clinical Trials Database record
- 18 Nov 2019 Planned End Date changed from 29 Nov 2019 to 2 Dec 2019.